These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N, Gökkurt E, Platzbecker U, Hollburg W, Göthert JR, Parmentier S, Lang F, Hansen R, Isfort S, Schmitt K, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S, Study Alliance Leukemia (SAL). J Hematol Oncol; 2016 Mar 05; 9():18. PubMed ID: 26944254 [Abstract] [Full Text] [Related]
64. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Intern Med; 1995 Nov 01; 123(9):656-64. PubMed ID: 7574220 [Abstract] [Full Text] [Related]
65. Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia. Pemmaraju N, Gerds AT, Yu J, Parasuraman S, Shah A, Xi A, Kumar S, Scherber RM, Verstovsek S. Leuk Res; 2022 Apr 01; 115():106809. PubMed ID: 35220060 [Abstract] [Full Text] [Related]
66. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Gerli G, Vianelli N, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Marchioli R, Leone G, Barbui T, GIMEMA CMD-Working Party. Haematologica; 2008 Mar 01; 93(3):372-80. PubMed ID: 18268279 [Abstract] [Full Text] [Related]
67. Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia. Michiels JJ, van Genderen PJ, Lindemans J, van Vliet HH. Leuk Lymphoma; 1996 Sep 01; 22 Suppl 1():47-56. PubMed ID: 8951772 [Abstract] [Full Text] [Related]
68. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Landolfi R, Cipriani MC, Novarese L. Best Pract Res Clin Haematol; 2006 Sep 01; 19(3):617-33. PubMed ID: 16781491 [Abstract] [Full Text] [Related]
69. Kinase drug discovery approaches in chronic myeloproliferative disorders. Kumar C, Purandare AV, Lee FY, Lorenzi MV. Oncogene; 2009 Jun 18; 28(24):2305-13. PubMed ID: 19421140 [Abstract] [Full Text] [Related]
70. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Michiels JJ, Berneman ZN, Schroyens W, Van Vliet HH. Platelets; 2004 Mar 18; 15(2):67-84. PubMed ID: 15154599 [Abstract] [Full Text] [Related]
71. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM. J Clin Oncol; 2007 Mar 20; 25(9):1048-53. PubMed ID: 17369568 [Abstract] [Full Text] [Related]
72. Real-world treatments and thrombotic events in polycythemia vera patients in the USA. Verstovsek S, Pemmaraju N, Reaven NL, Funk SE, Woody T, Valone F, Gupta S. Ann Hematol; 2023 Mar 20; 102(3):571-581. PubMed ID: 36637474 [Abstract] [Full Text] [Related]
73. Thrombotic complications of polycythemia vera. Varma S, Sharma A, Malhotra P, Kumari S, Jain S, Varma N. Hematology; 2008 Dec 20; 13(6):319-23. PubMed ID: 19055858 [Abstract] [Full Text] [Related]
74. Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera. Pósfai É, Marton I, Borbényi Z, Nemes A. Anatol J Cardiol; 2016 Jun 20; 16(6):397-402. PubMed ID: 27182615 [Abstract] [Full Text] [Related]
75. Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia Vera. Benevolo G, Marchetti M, Melchio R, Beggiato E, Sartori C, Biolé CA, Rapezzi D, Bruno B, Milan A. Vasc Health Risk Manag; 2023 Jun 20; 19():765-778. PubMed ID: 38025519 [Abstract] [Full Text] [Related]
76. Front-line therapy in polycythemia vera and essential thrombocythemia. Barbui T, Finazzi MC, Finazzi G. Blood Rev; 2012 Sep 20; 26(5):205-11. PubMed ID: 22784966 [Abstract] [Full Text] [Related]
77. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Alvarez-Larrán A, Martínez-Avilés L, Hernández-Boluda JC, Ferrer-Marín F, Antelo ML, Burgaleta C, Mata MI, Xicoy B, Martínez-Trillos A, Gómez-Casares MT, Durán MA, Marcote B, Ancochea A, Senín A, Angona A, Gómez M, Vicente V, Cervantes F, Bellosillo B, Besses C. Ann Hematol; 2014 Dec 20; 93(12):2037-43. PubMed ID: 24981691 [Abstract] [Full Text] [Related]
78. Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms. Seguro FS, Teixeira LLC, da Rosa LI, da Silva WF, Nardinelli L, Bendit I, Rocha V. J Thromb Thrombolysis; 2020 May 20; 49(4):667-672. PubMed ID: 31898273 [Abstract] [Full Text] [Related]
79. Spontaneous megakaryocyte colony formation in myeloproliferative disorders is not neutralizable by antibodies against IL3, IL6 and GM-CSF. Li Y, Hetet G, Maurer AM, Chait Y, Dhermy D, Briere J. Br J Haematol; 1994 Jul 20; 87(3):471-6. PubMed ID: 7993786 [Abstract] [Full Text] [Related]